Moderna Flu Breakthrough And Hantavirus Push Reframe Long Term Story

Moderna reported positive Phase 3 results for its mRNA seasonal influenza vaccine candidate, mRNA-1010, showing stronger ...

Moderna stock rises on positive phase 3 flu data: What investors need to know

Moderna Inc MRNA shares are trading higher Friday morning as traders react to peer reviewed Phase 3 flu-vaccine data. Here’s ...

Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010

Regulatory filings are under review in the U.S., Europe, Canada and Australia, with potential approvals expected to ...
Hosted on MSN

Moderna shares surge 14% on positive hantavirus vaccine trial data

Stock jumps on data: Shares rose 14% after Phase 1 results showed strong immune responses and no serious safety issues for Moderna’s hantavirus vaccine. Platform potential: Analysts see the results as ...
News.az

Moderna stock jumps after hantavirus vaccine update

This development renewed investor confidence in Moderna’s mRNA pipeline, even as a cluster of hantavirus cases emerged on a ...
Nasdaq

Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent ...

Moderna’s mRNA Melanoma Data And Fast Track Status Shape Oncology Story

Moderna (NasdaqGS:MRNA) plans to present Phase 1/2 data for its mRNA-4359 cancer antigen therapy combined with pembrolizumab in advanced melanoma at the 2026 AACR Annual Meeting. The company reports ...
The National Law Review

Moderna Announces Data to be Presented at ESMO Congress 2025

CAMBRIDGE, MA / ACCESS Newswire / July 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its investigational mRNA therapeutics have been accepted for presentation at the ...
Detroit Free Press

Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026

CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010, ...
USA Today

Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting

Abstract #9500: Individualized neoantigen therapy intismeran autogene (intismeran) plus pembrolizumab (pembro) in resected melanoma: 5-year update of the KEYNOTE-942 study Intismeran autogene is ...
Nasdaq

Moderna Clinical Trial Data Confirm Its Updated Covid-19 Vaccine Generates Strong Immune Response in Humans Against BA.2.86

CDC notes that the BA.2.86 (Pirola) variant may be more likely to break through existing immunity from previous vaccination or infection, highlighting the need for vaccination with an updated COVID-19 ...
GEN

StockWatch: Positive Cancer Vaccine Data Wows Moderna Investors

No sooner did Moderna (MRNA) and Merck & Co. (MRK) announce additional positive data for their cancer vaccine candidate, a messenger RNA (mRNA)-based individualized neoantigen therapy (INT), than ...